• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ZimVie to Report Third Quarter Financial Results on October 30, 2024

    10/16/24 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email

    PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

    Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com

    About ZimVie

    ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

    Media Contact Information:

    ZimVie

    Grace Flowers • [email protected]

    (561) 319-6130

    Investor Contact Information:

    Gilmartin Group LLC

    Marissa Bych • [email protected]



    Primary Logo

    Get the next $ZIMV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will ZimVie Inc. announce its third quarter financial results?

      ZimVie Inc. is scheduled to report its third quarter financial results on October 30, 2024, after market close.

    • What time is the conference call for ZimVie Inc.'s third quarter financial results?

      The conference call to discuss the financial results will begin at 4:30 p.m. Eastern Time on the same day that results are announced.

    • How can individuals participate in the ZimVie Inc. conference call?

      Interested participants can register online to listen to the conference call, and they are encouraged to register more than 15 minutes before the call starts.

    • What is ZimVie Inc.'s main business focus?

      ZimVie Inc. is a global leader in the dental market, focusing on developing products for dental tooth replacement and restoration procedures.

    • Will there be a replay available for ZimVie Inc.'s conference call?

      A replay of the conference call will be available on the investor section of the ZimVie website after the live event.

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    3/18/2022Neutral
    Guggenheim
    More analyst ratings